Patients with chronic kidney disease are at an elevated risk of dementia: A population-based cohort study in Taiwan

BMC Nephrology

Fung-Chang Sung²  Pang-Yao Tsai²  Chih-Hsin Mou²  Shih-Wei Lai³  Yu-Lung Chen¹  Kao-Chi Cheng¹ 

[1]Department of Family Medicine, China Medical University Hospital, Taichung, 404, Taiwan

[2]Department of Public Health, China Medical University, Taichung, 404, Taiwan

[3]School of Medicine, China Medical University, 91 Hsueh-Shih Road, Taichung, 404, Taiwan

关键词: Retrospective cohort study;    Medication;    Dementia;    Comorbidity;    Chronic kidney disease;   

Others  :  1083082
DOI  :  10.1186/1471-2369-13-129

 received in 2011-12-23, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Chronic kidney disease (CKD) is more prevalent in Taiwan than in most countries. This population-based cohort study evaluated the dementia risk associated with CKD.

Methods

Using claims data of 1,000,000 insured residents covered in the universal health insurance of Taiwan, we selected 37049 adults with CKD newly diagnosed from 2000–2006 as the CKD cohort. We also randomly selected 74098 persons free from CKD and other kidney diseases, frequency matched with age, sex and the date of CKD diagnosed. Incidence and hazard ratios (HRs) of dementia were evaluated by the end of 2009.

Results

Subjects in the CKD cohort were more prevalent with comorbidities than those in the non-CKD cohort (p <0.0001). The dementia incidence was higher in the CKD cohort than in the non-CKD cohort (9.30 vs. 5.55 per 1,000 person-years), with an overall HR of 1.41 (95% confidence interval (CI), 1.32-1.50), controlling for sex, age, comorbidities and medicaitions. The risk was similar in men and women but increased sharply with age to an HR of 133 (95% CI, 68.9-256) for the elderly. However, the age-specific CKD cohort to non-CKD cohort incidence rate ratio decreased with age, with the highest ratio of 16.0 (95% CI, 2.00-128) in the youngest group. Among comorbidities and medications, alcoholism and taking benzodiazepines were also associated with dementia with elevated adjusted HRs of 3.05 (95% CI 2.17-4.28) and 1.23 (95% CI 1.14-1.32), respectively.

Conclusions

Patients with CKD could have an elevated dementia risk. CKD patients with comorbidity deserve attention to prevent dementia.

【 授权许可】

   
2012 Cheng et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hwang SJ, Tsai JC, Chen HC: Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton) 2010, 15(Suppl 2):3-9.
• [2]Kuo HW, Tsai SS, Tiao MM, Yang CY: Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007, 49(1):46-55.
• [3]Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al.: Excerpts from the United States Renal Data System 2004 annual data report:atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005, 45(Suppl 1):5-7.
• [4]Abbasi M, Chertow G, Hall Y: End-stage Renal Disease. Am Fam Physician 2010, 82(12):1512.
• [5]Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12(12):2753-2758.
• [6]Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):038-2047.
• [7]Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al.: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephro 2007, 11(2):156-163.
• [8]Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, Horng SS, Chang YK, Yang WC: High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006, 48(5):727-738.
• [9]Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008, 8:117-129. BioMed Central Full Text
• [10]Seliger SL, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH: Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004, 15(7):1904-1911.
• [11]Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, et al.: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998, 105(4–5):423-438.
• [12]Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998, 351(9119):1840-1843.
• [13]Fuh JL, Wang SJ: Dementia in Taiwan: past, present, and future. Acta Neurol Taiwan 2008, 17(3):153-161.
• [14]Sasaki Y, Marioni R, Kasai M, Ishii H, Yamaguchi S, Meguro K: Chronic kidney disease: a risk factor for dementia onset: a population-based study. The Osaki-Tajiri Project. J Am Geriatr Soc 2011, 59(7):1175-1181.
• [15]Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, Allman RM, Warnock DG, McClellan W: Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008, 52(2):227-234.
• [16]Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, et al.: Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc 2010, 58(2):338-345.
• [17]Weng SC, Shu KH, Tang YJ, Sheu WH, Tarng DC, Wu MJ, et al.: Progression of cognitive dysfunction in elderly chronic kidney disease patients in a veteran's institution in central Taiwan: a 3-year longitudinal study. Intern Med 2012, 51(1):29-35.
• [18]Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC: Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010, 89(5):295-299.
• [19]Lai SW, Muo CH, Liao KF, Sung FC, Chen PC: Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011, 106(9):1697-1704.
• [20]Lai SW, Su LT, Lin CH, Tsai CH, Sung FC, Hsieh DP: Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: a population-based study. Psychogeriatrics 2011, 11(3):150-156.
• [21]Nickolas TL, Khatri M, Boden-Albala B, Kiryluk K, Luo X, Gervasi-Franklin P, Paik M, Sacco RL: The association between kidney disease and cardiovascular risk in a multiethnic cohort: findings from the Northern Manhattan Study (NOMAS). Stroke 2008, 39(10):2876-2879.
• [22]Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, Sacco RL, DeCarli C: Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007, 38(12):3121-3126.
• [23]Vliet PV: Cholesterol and Late-Life Cognitive Decline. J Alzheimers Dis 2012, 30:S147-S162.
• [24]Khatri M, Nickolas T, Moon YP, Paik MC, Rundek T, Elkind MS, Sacco RL, Wright CB: CKD associates with cognitive decline. J Am Soc Nephrol 2009, 20(11):2427-2432.
• [25]Qiu C, Winblad B, Fratiglioni L: The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005, 4(8):487-499.
• [26]Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347(9009):1141-1145.
• [27]Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L, Palomaki H, Kaste M: Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995, 73(4):558-560.
• [28]Lee PN: Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994, 13(4):131-144.
• [29]Scherr PA, Hebert LE, Smith LA, Evans DA: Relation of blood pressure to cognitive function in the elderly. Am J Epidemiol 1991, 134(11):303-1315.
• [30]Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63(7):1181-1186.
• [31]McCall AL: The impact of diabetes on the CNS. Diabetes 1992, 41(5):557-570.
• [32]Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5(1):64-74.
• [33]Aronson MK, Ooi WL, Morgenstern H, Hafner A, Masur D, Crystal H, Frishman WH, Fisher D, Katzman R: Women, myocardial infarction, and dementia in the very old. Neurology 1990, 40(7):1102-1106.
• [34]Breteler MM, Claus JJ, Grobbee DE, Hofman A: Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. Bmj 1994, 308(6944):1604-1608.
• [35]Breteler M: Vascular risk factors for Alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 2000, 21(2):153-160.
• [36]Guo Z, Viitanen M, Fratiglioni L, Winblad B: Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 1996, 312(7034):805-808.
• [37]Lindsay J, Hebert R, Rockwood K: The Canadian Study of Health and Aging: risk factors for vascular dementia. Stroke 1997, 28(3):526-530.
• [38]Anstey KJ, Mack HA, Cherbuin N: Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry 2009, 17(7):542-555.
• [39]Sinforiani E, Zucchella C, Pasotti C, Casoni F, Bini P, Costa A: The effects of alcohol on cognition in the elderly: from protection to neurodegeneration. Funct Neurol 2011, 26:103-106.
• [40]Knopman DS: Cerebrovascular disease and dementia. Br J Radiol 2007, 80(Spec 2):121-127.
• [41]Onyike CU: Cerebrovascular disease and dementia. Int Rev Psychiatry 2006, 18(5):423-431.
• [42]Srikanth V, Saling MM, Thrift AG, Donnan GA: Cerebrovascular disease and dementia. Drug Today (Barc) 2005, 41(12):815-825.
• [43]Kovacic JC, Castellano JM, Fuster V: The links between complex coronary disease, cerebrovascular, disease, and degenerative brain disease. Ann N Y Acad Sci 2012, 1254(1):99-105.
• [44]Deramecourt V, Slade JY, Oakley AE, Perry RH, Ince PG, Maurage CA, Kalaria RN: Staging and natural historyof cerebrovascular pathology indementia. Neurology 2012, 78(14):1043-1050.
• [45]Padovani A, Costanzi C, Gilberti N, Borroni B: Parkinson's disease and dementia. Neurol Sci 2006, 27(Suppl 1):40-43.
• [46]Porter RJ, Gallagher P, Thompson JM, Young AH: Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003, 182:214-220.
• [47]Vogels SC, Emmelot-Vonk MH, Verhaar HJ, Koek HD: The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review. Maturitas 2012, 7(4):331-336.
• [48]Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004, 18(1):37-48.
• [49]Verdoux H, Lagnaoui R, Begaud B: Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005, 35(3):307-315.
• [50]Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008, 16(5):343-354.
• [51]Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP: Dementia associated with alcohol and other drug use. Int Psychogeriatr 2005, 17(Suppl 1):109-127.
• [52]Goldstein FC, Ashley AV, Endeshaw YW, Hanfelt J, Lah JJ, Levey AI: Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with alzheimer disease. Alzheimer Dis Assoc Disord 2008, 22(4):336-342.
• [53]Thoonsen H, Richard E, Bentham P, Gray R, van Geloven N, de Haan RJ, van Gool WA, Nederkoorn PJ: Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern. Stroke 2010, 41(11):2690-2692.